Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis.

ABSTRACT:

Background

Fibrostenotic disease is a common complication in Crohn's disease (CD) patients hallmarked by transmural extracellular matrix (ECM) accumulation in the intestinal wall. The prevention and medical therapy of fibrostenotic CD is an unmet high clinical need. Although targeting IL36R signaling is a promising therapy option, downstream mediators of IL36 during inflammation and fibrosis have been incompletely understood. Candidate molecules include matrix metalloproteinases which mediate ECM turnover and are thereby potential targets for anti-fibrotic treatment. Here, we have focused on understanding the role of MMP13 during intestinal fibrosis.

Methods

We performed bulk RNA sequencing of paired colon biopsies taken from non-stenotic and stenotic areas of patients with

SUBMITTER: Koop K 

PROVIDER: S-EPMC10189878 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature